Evaluations of NSAIDs and Opioids as Analgesics in Pediatric Oncology

Eduardo Ladeia Leal, Paulo Caleb Júnior Lima Santos, T. S. Gonçalves, Mariana Martins Gonzaga Nascimento, Fábio Cardoso Cruz, Flávia Borelli Gomes do Nascimento, Carolina Paula Jesus Kasa
{"title":"Evaluations of NSAIDs and Opioids as Analgesics in Pediatric Oncology","authors":"Eduardo Ladeia Leal, Paulo Caleb Júnior Lima Santos, T. S. Gonçalves, Mariana Martins Gonzaga Nascimento, Fábio Cardoso Cruz, Flávia Borelli Gomes do Nascimento, Carolina Paula Jesus Kasa","doi":"10.3390/futurepharmacol3040055","DOIUrl":null,"url":null,"abstract":"As one of the leading causes of death in childhood, cancer also causes discomfort to pediatric patients. Even with guidelines for pain management, more than half of hospitalized children have intense and unrelieved pain. The present work aims to describe the intensity of pain and its pharmacological management in a pediatric oncology population. Patients aged 0 to 17 years old, diagnosed with cancer, who were admitted to a children’s oncology hospital and had well-documented data on pain management in their medical records were included. A total of 333 patients were included, mostly male (55.8%) with a mean age of 7.9 years. A substantial portion of the patient cohort (51.4%) initially reported experiencing pain of moderate intensity during the first assessment. Subsequently, following the pharmacological intervention, a significant proportion of patients (90.1%) reported complete alleviation of pain. The predominant pharmaceutical agents utilized for pain management encompassed metamizole (76.6%) and morphine (10.2%). All pharmacological interventions used were able to significantly reduce patients’ pain. This study underscores the utilization of different pharmacological classes to achieve notable reductions in pain intensity among patients grappling with severe pain.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/futurepharmacol3040055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As one of the leading causes of death in childhood, cancer also causes discomfort to pediatric patients. Even with guidelines for pain management, more than half of hospitalized children have intense and unrelieved pain. The present work aims to describe the intensity of pain and its pharmacological management in a pediatric oncology population. Patients aged 0 to 17 years old, diagnosed with cancer, who were admitted to a children’s oncology hospital and had well-documented data on pain management in their medical records were included. A total of 333 patients were included, mostly male (55.8%) with a mean age of 7.9 years. A substantial portion of the patient cohort (51.4%) initially reported experiencing pain of moderate intensity during the first assessment. Subsequently, following the pharmacological intervention, a significant proportion of patients (90.1%) reported complete alleviation of pain. The predominant pharmaceutical agents utilized for pain management encompassed metamizole (76.6%) and morphine (10.2%). All pharmacological interventions used were able to significantly reduce patients’ pain. This study underscores the utilization of different pharmacological classes to achieve notable reductions in pain intensity among patients grappling with severe pain.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估非甾体抗炎药和阿片类药物在儿科肿瘤中的镇痛作用
作为儿童死亡的主要原因之一,癌症也会给儿科患者带来不适。即使有疼痛管理指南,超过一半的住院儿童仍有强烈且无法缓解的疼痛。目前的工作旨在描述疼痛的强度和它的药理学管理在儿科肿瘤人群。年龄在0到17岁之间,被诊断患有癌症,在儿童肿瘤医院住院,并且在其医疗记录中有关于疼痛管理的良好记录的患者被纳入研究。共纳入333例患者,以男性为主(55.8%),平均年龄7.9岁。很大一部分患者队列(51.4%)最初报告在第一次评估时经历中等强度的疼痛。随后,经过药物干预,相当比例的患者(90.1%)报告疼痛完全缓解。用于疼痛管理的主要药物包括安美唑(76.6%)和吗啡(10.2%)。所有的药物干预都能显著减轻患者的疼痛。这项研究强调利用不同的药理学类,以达到显著减少疼痛强度的患者与严重疼痛的斗争。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
In Vitro and In Silico Biological Evaluation of the Essential Oil from Syzigium cumini Leaves as a Source of Novel Antifungal and Trichomonacidal Agents Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future Comparative Study of the Effects of Curcuminoids and Tetrahydrocurcuminoids on Melanogenesis: Role of the Methoxy Groups Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review Target-Based 6-5 Fused Ring Heterocyclic Scaffolds Display Broad Antiparasitic Potency In Vitro
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1